Related Experiment Video
Updated: Jan 23, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
[A clinical experience with CAR-T cell therapy brexu-cel as salvage option for a Relapsed/Refractory patient with
Jacopo Nanni1, Federica Ardizzoia1
1Dipartimento di Scienze mediche e chirurgiche, Università di Bologna - Irccs Azienda ospedaliero-universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna.
Abstract:
Brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, is a promising and available salvage option for relapsed/refractory philadelphia-positive B-Cell Acute Lymphoblastic Leukemia patients, potentially effective even after several previous lines of therapy and a previous allogeneic stem cell transplant (HSCT). This reported clinical case allowed us to highlight different relevant factors for the optimal, complex and multidisciplinary management of this subgroup of patients: bridging therapy selection, the need of reevaluating CD19 expression, disease burden as an outcome predictor and the role of HSCT as a further therapeutic consolidation.
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Kidney Injury III: Clinical Manifestations
Chronic Kidney Disease II: Clinical Manifestations
Clinical Applications of Epidermal Stem Cells
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

